Dr. Dominique Demolle is a member of Quotient Sciences' Scientific Advisory Board.

Dr. Demolle is the co-founder and CEO of Cognivia, a company leveraging machine learning and patient psychology to reduce data variability and improve the conduct of clinical trials. 

With decades of experience in clinical development, including her role as Associate Director of Global Early Phase Operations at Eli Lilly, and her efforts in building partnerships with pharmaceutical and biotech companies, she demonstrated the importance of understanding patient behavior in drug development. Her commitment to creating innovative technology aims to prevent therapy failures due to treatment nonadherence, dropout, patient heterogeneity, and placebo response. 

Dominique earned her PhD in Biochemistry from the University of Brussels and was honored as one of the Most Inspiring People in Life Sciences by the 2022 PharmaVoice 100 awards.